Published in Antimicrob Agents Chemother on November 01, 1999
Biological cost of rifampin resistance from the perspective of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 1.79
Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase beta subunit) of Streptomyces lividans. J Bacteriol (2002) 1.55
Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob Agents Chemother (2006) 1.54
Novel approach for improving the productivity of antibiotic-producing strains by inducing combined resistant mutations. Appl Environ Microbiol (2001) 1.33
RNA polymerase inhibitors with activity against rifampin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother (2000) 1.31
Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother (2011) 1.27
Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil. Antimicrob Agents Chemother (2005) 1.22
Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis. Antimicrob Agents Chemother (2003) 1.17
In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2006) 1.16
rpoB mutation conferring rifampin resistance in Streptococcus pyogenes. Antimicrob Agents Chemother (2002) 1.15
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother (2009) 1.09
Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother (2000) 1.09
Antimicrobial resistance induced by genetic changes. J Med Life (2010) 1.04
Impact of ciprofloxacin exposure on Staphylococcus aureus genomic alterations linked with emergence of rifampin resistance. Antimicrob Agents Chemother (2011) 0.97
Synergism between Medihoney and rifampicin against methicillin-resistant Staphylococcus aureus (MRSA). PLoS One (2013) 0.96
Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain. BMC Microbiol (2010) 0.92
Genetic basis of rifampicin resistance in methicillin-resistant Staphylococcus aureus suggests clonal expansion in hospitals in Cape Town, South Africa. BMC Microbiol (2012) 0.84
EshA accentuates ppGpp accumulation and is conditionally required for antibiotic production in Streptomyces coelicolor A3(2). J Bacteriol (2006) 0.84
Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection. Antimicrob Agents Chemother (2006) 0.83
rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin. Antimicrob Agents Chemother (2004) 0.82
Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.82
RNA-Seq reveals differential gene expression in Staphylococcus aureus with single-nucleotide resolution. PLoS One (2013) 0.80
Molecular characterization of rifampicin-resistant Staphylococcus aureus isolates in a Chinese teaching hospital from Anhui, China. BMC Microbiol (2012) 0.78
Simultaneous species identification and detection of rifampicin resistance in staphylococci by sequencing of the rpoB gene. Eur J Clin Microbiol Infect Dis (2008) 0.76
Influence of a non-hospital medical care facility on antimicrobial resistance in wastewater. PLoS One (2015) 0.75
Update on rifampin resistance in the Legionellaceae. Antimicrob Agents Chemother (2001) 0.75
Rifampicin-Resistance Mutations in the rpoB Gene in Bacillus velezensis CC09 have Pleiotropic Effects. Front Microbiol (2017) 0.75
Evolution of antibiotic resistance without antibiotic exposure. Antimicrob Agents Chemother (2017) 0.75
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet (1993) 16.75
Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol (1988) 8.26
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev (1997) 6.98
Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis (1994) 5.28
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet (1997) 4.77
The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1994) 3.78
Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother (1993) 3.46
Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother (1998) 3.41
Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis. FEMS Microbiol Lett (1996) 3.40
The primary structure of Escherichia coli RNA polymerase. Nucleotide sequence of the rpoB gene and amino-acid sequence of the beta-subunit. Eur J Biochem (1981) 3.32
Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (1998) 3.15
Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the beta subunit of Escherichia coli RNA polymerase. J Biol Chem (1993) 3.07
Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother (1998) 2.58
Rifampin: mechanisms of action and resistance. Rev Infect Dis (1983) 2.23
Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother (1995) 2.22
Molecular characterization of rifampin-resistant Neisseria meningitidis. Antimicrob Agents Chemother (1994) 1.70
Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother (1998) 1.54
RifR mutations in the beginning of the Escherichia coli rpoB gene. Mol Gen Genet (1994) 1.52
Antimicrobial activity of rifabutin. Clin Infect Dis (1996) 1.40
The beta subunit Rif-cluster I is only angstroms away from the active center of Escherichia coli RNA polymerase. J Biol Chem (1995) 1.35
In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. Antimicrob Agents Chemother (1994) 1.19
Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1997) 1.13
Nucleotide sequence of the Staphylococcus aureus RNA polymerase rpoB gene and comparison of its predicted amino acid sequence with those of other bacteria. Biochim Biophys Acta (1995) 1.05
Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? Int J Antimicrob Agents (1997) 0.94
Genetic analysis of Staphylococcus aureus RNA polymerase mutants. J Bacteriol (1979) 0.89
16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. J Clin Microbiol (2006) 3.25
Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and Factor H. Eur J Immunol (2001) 2.30
Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect (2009) 2.28
Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest (1978) 2.24
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect Immun (2001) 2.02
Kinetic studies of the formation of the properdin system enzymes on zymosan: evidence that nascent C3b controls the rate of assembly. J Immunol (1974) 1.82
In vitro synthesis of factor B of the alternative pathway of complement activation by mouse peritoneal macrophages. Eur J Immunol (1976) 1.78
Mechanism of YadA-mediated serum resistance of Yersinia enterocolitica serotype O3. Infect Immun (1992) 1.61
Interaction of C3b, B, and D in the alternative pathway of complement activation. J Immunol (1975) 1.55
Preventing post-treatment bacteremia: comparing topical povidone-iodine and chlorhexidine. J Am Dent Assoc (1995) 1.50
Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates. Int Immunopharmacol (2001) 1.45
Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes. J Immunol (1974) 1.44
Heterogeneity in the complement-dependent bacteriolysis within the species of Borrelia burgdorferi. Med Microbiol Immunol (1997) 1.44
Removal of PCR inhibitors by silica membranes: evaluating the Amplicor Mycobacterium tuberculosis kit. J Clin Microbiol (2001) 1.41
Two cases of chronic arthritis of the forearm due to Mycobacterium tuberculosis. Eur J Clin Microbiol Infect Dis (1998) 1.41
Rapid molecular typing of methicillin-resistant Staphylococcus aureus by PCR-RFLP. Infect Control Hosp Epidemiol (2001) 1.28
Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother (2001) 1.28
The reaction of zymosan with the properdin system: isolation of purified factor D from guinea pig serum and study of its reaction characteristics. J Immunol (1974) 1.24
Biosynthesis of pro-C3, a precursor of the third component of complement. J Exp Med (1977) 1.23
T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum (1991) 1.23
Dextran sulphate: a synthetic activator of C3 via the alternative pathway. I. Influence of molecular size and degree of sulphation on the activation potency. Immunology (1975) 1.22
Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro. Immunology (1978) 1.21
Inherited polymorphism of guinea pig factor B and C4: evidence for genetic linkage between the C4 and Bf loci. J Immunol (1977) 1.19
Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin Exp Allergy (2000) 1.15
Clonal heterogeneity, distribution, and pathogenicity of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1997) 1.13
Mouse factor B of the alternative pathway of complement activation. I. Purification, characterization, and functional behavior. J Immunol (1976) 1.11
Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp--a molecular-epidemiological study. Wien Klin Wochenschr (2000) 1.10
Comparison of two laboratory methods for the determination of serum resistance in Borrelia burgdorferi isolates. Immunobiology (2000) 1.09
Studies on the properdin system: isolation of a heat-labile factor from guinea pig serum related to a human glycine rich beta-glycoprotein (GBG or factor B). J Immunol (1972) 1.07
Antimicrobial effectiveness of povidone-iodine and consequences for new application areas. Dermatology (2002) 1.04
Influence of surface modulations by enzymes and monoclonal antibodies on alternative complement pathway activation by Yersinia enterocolitica. Infect Immun (1989) 1.03
Purification and some properties of a heat labile serum factor (UP); identity with glycine-rich beta-glycoprotein and properdin factor B. Hoppe Seylers Z Physiol Chem (1973) 1.03
Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant. J Med Microbiol (2000) 1.02
Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemotherapy. Support Care Cancer (1998) 1.02
In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother (2001) 0.99
[The glutamic acid decarboxylase disc test. An approach for the simplification and speeding up of E. coli detection]. Zentralbl Bakteriol Mikrobiol Hyg B (1988) 0.98
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. J Antimicrob Chemother (2001) 0.97
Development and evaluation of a molecular assay for detection of nontuberculous mycobacteria by use of the cobas amplicor platform. J Clin Microbiol (2008) 0.96
Serologic evidence for tick-borne pathogens other than Borrelia burgdorferi (TOBB) in Lyme borreliosis patients from midwestern Germany. Wien Klin Wochenschr (1998) 0.95
Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol Lett (2000) 0.94
Colorimetric in vitro susceptibility testing of penicillins, cephalosporins, macrolides, streptogramins, tetracyclines, and aminoglycosides against Borrelia burgdorferi isolates. Int J Antimicrob Agents (2000) 0.93
Rapid detection of epidemic strains of methicillin-resistant Staphylococcus aureus. J Clin Microbiol (1999) 0.93
Serotyping, sites of isolation and resistance of Pseudomonas aeruginosa. Microbiologica (1988) 0.92
[Serodiagnosis of Lyme borreliosis: antibody titer and specificity in the IFT and western blot]. Immun Infekt (1989) 0.92
Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol (2010) 0.91
New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances. Eur J Clin Microbiol Infect Dis (2000) 0.91
Incompatibility between C3b and B of guinea-pig and man and its influence on the titration of the alternative pathway factors D and B in these two species. Immunology (1976) 0.91
Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection (2005) 0.91
Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway. Z Immunitatsforsch Immunobiol (1977) 0.87
Zoonotic Babesia: possibly emerging pathogens to be considered for tick-infested humans in Central Europe. Int J Med Microbiol (2004) 0.87
Transduction of resistance to Imipenem, Aztreonam and Ceftazidime in nosocomial strains of Pseudomonas aeruginosa by wild-type phages. Acta Virol (1993) 0.86
Extended-spectrum beta-lactamase producing strains of Enterobacter cloacae transferring resistance to cefotaxime and ceftazidime. J Chemother (1999) 0.85
Role of quantitative cultures and microscopic examinations of endotracheal aspirates in the diagnosis of pulmonary infections in ventilated patients. J Hosp Infect (1997) 0.84
Six enteropathogens isolated from a case of acute gastroenteritis. Infection (1991) 0.84
Mycobacterium malmoense infections in immunocompetent patients. Eur J Clin Microbiol Infect Dis (1999) 0.83
Medical and veterinary use of antimicrobial agents: implications for public health. A clinician's view on antimicrobial resistance. Vet Microbiol (1993) 0.83
Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) (2000) 0.83
Evaluation of modern agglutination tests for identification of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1999) 0.83
Effect of in vivo stimulation of mice on the secretion of factor B of the alternate complement pathway by peritoneal macrophages. Eur J Immunol (1977) 0.83
Imipenem and cefotaxime resistance: transduction by wild-type phages in hospital strains of Pseudomonas aeruginosa. J Chemother (1992) 0.83
Formation of EAC142 and EAC1423 with macrophage culture supernatant containing the secreted complement components C1 to C3. Immunobiology (1984) 0.82
Lyme arthritis in a 12-year-old patient after a latency period of 5 years. Infection (1999) 0.82
Frequency, clonal heterogeneity and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) isolated in 1992-1994. Zentralbl Bakteriol (1996) 0.82
Evasion of Yersinia enterocolitica serotype 03 from complement-mediated killing. Behring Inst Mitt (1991) 0.81
Leprosy in a pregnant woman. Infection (2007) 0.81
Functional active complement components secreted by guinea pig peritoneal macrophages. Immunobiology (1982) 0.80
Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers. J Antimicrob Chemother (1988) 0.80
Epidemiology of penicillin-resistant Neisseria gonorrhoeae in Frankfurt, Germany. Eur J Clin Microbiol Infect Dis (1995) 0.80
[Tick bite and Lyme borreliosis. An epidemiologic study in the Erlangen area]. Monatsschr Kinderheilkd (1993) 0.80
[Congenital toxoplasmosis with delayed immune response in children. Diagnostic problems]. Dtsch Med Wochenschr (1987) 0.79
In vitro activity of mezlocillin, meropenem, aztreonam, vancomycin, teicoplanin, ribostamycin and fusidic acid against Borrelia burgdorferi. Int J Antimicrob Agents (2001) 0.79
[Spontaneous gas gangrene in a diabetic patient with Clostridium septicum]. Chirurg (2005) 0.79
Preliminary results of an interdisciplinary survey of drug victims. Forensic Sci Int (1993) 0.79
Further studies of transferable antibiotic resistance in strains of Pseudomonas aeruginosa from four clinical settings in three countries. J Chemother (1998) 0.78
Bacteriophages transducing antibiotic resistance from a cluster of lysogenic strains of Pseudomonas aeruginosa isolated from patients. J Chemother (2001) 0.78
Disseminated cutaneous Mycobacterium marinum infection in a patient with non-Hodgkin's lymphoma. Infection (2002) 0.78
In vitro susceptibility of the Borrelia burgdorferi sensu lato complex to ABT-773, a novel ketolide. J Antimicrob Chemother (2001) 0.78
C3 activation by a new factor B-dependent enzyme detected in culture supernatant from guinea-pig peritoneal macrophages. Immunology (1986) 0.78
[Osteomyelitis of the tibial head caused by Mycobacterium haemophilium in a patient with AIDS]. Dtsch Med Wochenschr (2002) 0.78
Interaction of lipopolysaccharides and of lipid A from Yersinia enterocolitica with purified guinea pig C3. Immunobiology (1980) 0.78
Influence of fosfomycin on the intestinal and pharyngeal flora of man. Infection (1991) 0.78
CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis (2013) 0.78
Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates. Microbiological and Clinical Study Groups. J Antimicrob Chemother (1992) 0.78
Prevalence of antibodies against the human granulocytic ehrlichiosis agent in Lyme borreliosis patients from Germany. Eur J Clin Microbiol Infect Dis (1999) 0.78